UBI集團訊息
UBP Presents at Antibody Drug Development Conference Plans to submit Phase I Clinical Trial application in 2017 for UB-221, a third-generation anti-IgE monoclonal antibody drug
UB-221, which is considered a third-generation anti-IgE monoclonal antibody drug. UB-221 contains the advantages of “neutralization of free-IgE” and “blockade of B cell-mediated IgE synthesis,”was co-invented by Xolair® inventor, Dr. Tse-Wen Chang, and his Ph.D. students, Dr. Jiun-Bo Chen and Dr. Yu-Yu Shiung, Several biological activity studies have shown that UB-221 has better affinity to IgE and superior pharmacological property than Xolair® and Anti-CεmX.
UBP licensed UB-221 from Academia Sinica in October 2014, and has fully engaged UB-221 in pharmacological studies. UBP has developed a stable and high-yield cell line and antibody production technology for UB-221. UB-221 pre-clinical drug development stage and can be applied in the treatment of IgE-mediated diseases including asthma, allergic rhinitis, atopic dermatitis, food allergy and chronic idiopathic urticarial. UB-221 shows strong market potential in the future.
About UBP (6471)
UBP was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnering with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs of mankind. and For more information, please visit http://www.unitedbiopharma.com
United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.